Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
Provided By PR Newswire
Last update: Nov 4, 2024
Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM)
Company updates to corporate presentation and participation in upcoming medical meetings
Read more at prnewswire.com1.18
+0.33 (+39.63%)
Find more stocks in the Stock Screener
KZIA Latest News and Analysis
2 days ago - ChartmillWhich stocks are moving after the closing bell on Friday?Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
2 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
